secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenon Pharmaceuticals Inc. (XENE)
CIK:        0001582313
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0000950170-23-019727
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenon reports Q1 2023 net loss $41.7M; advances XEN1101 Phase 3 epilepsy trials
-------------------------------------------------------------------------------

- Net loss $41.7M ($0.66 per share) vs $19.7M in Q1 2022; no revenue recognized.
- R&D expenses $39.5M, up $20.2M YoY driven by XEN1101 Phase 3 studies and X-NOVA MDD trial.
- Cash $687.3M as of March 31, 2023; expects to fund operations into 2026.
- XEN1101 Phase 3 epilepsy trials (X-TOLE2, X-TOLE3, X-ACKT) recruiting; pediatric expansion to include children ≥12.
- Phase 2 X-NOVA MDD study last patient screening expected June 2023; topline data Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023019727/0000950170-23-019727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582313/000095017023019727/xene-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-019727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer